Despite the market’s big comeback in 2023, there is still one issue keeping positive sentiment in check; the prospect of a looming recession remains real. Nevertheless, J.P. Morgan Wealth Management’s Global Investment Strategist Elyse Ausenbaugh thinks investors have reason to be upbeat. “There are actually a lot of things for investors to feel pretty good about right now – starting with the economy,” Ausenbaugh opined. “In spite of higher interest rates, the economy has stayed a lot more resil
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals Inc (NASDAQ: MIRM). Mirum will purchase Travere's bile acid product portfolio for up to $445 million, consisting of $210 million upfront and $235 million in potential sales-based milestone payments. Mirum will acquire Travere's rights to Cholbam, indicated for bile acid synthesis disorders due to
SAN DIEGO, June 01, 2023 Travere Therapeutics, Inc. today announced that Company management will participate in the following upcoming conferences: William Blair 43rd Annual Growth Stock. | June 1, 2023